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ABSTRACT 
In the present study, the contractility of isolated 
cardiac muscle obtained from normotensive and treated or 
untreated hypertensive rat hearts were investigated. The 
effects of inotropic agents were also explored • 
. Some SHRs were subjected to chronic antihypertensive 
treatment. After their blood pressure had been lowered, 
positive and negative inotropic agents were used to study 
the papillary muscles. The effects of acidosis, increased 
extracellular calcium, hypoxia, and reoxygenation on the 
isolated papillary muscles obtained from their hearts were 
studied. The same was done for isolated cardiac muscles 
that were removed from WKYs and SHRs. Isoproterenol in the 
absence or presence of propranolol was also used to inves-
tigate the contractility of SHRs and WKYs. 
Clonidine, alpha-methyldopa, and verapamil all 
reduced the blood pressures of SHRs which were on chronic 
antihypertensive therapy. When propranolol was added to 
the muscle bath, the developed tension of the SHRs was 
significantly higher than that of the WKYs by 13.1% 
(p<O.OS) after 5 minutes of the addition showing that 
SHRs and WKYs behaved differently during this intervention. 
During the isoproterenol intervention in the absence of 
propranolol, the maximal rate of tension development after 
iii 
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10 minutes of addition of isoproterenol of the SHRs was 
significantly lower than their control measurement, while 
that of the WKYs was equal to their control. Also the time 
to maximal relaxation of the WKYs was significantly lower 
than the control. There was no change observed for the 
SHRs in their time to maximal relaxation before and after 
the isoproterenol was added to the bath. The developed 
tension and maximal rate of tension development of the WKYs 
improved significantly when isoproterenol was added to the 
bath following propranolol intervention. Overall the 
isoproterenol did not have any significant inotropic effect 
on SHRs and WKYs. During acidosis, the WKYs and pretreated 
rats responded equally but significantly lower than the SHRs. 
The developed tension, maximal rate of t ension development, 
and maximal rate of tension decline of WKYs were signifi-
cantly higher than those of the SHRs after 5 minutes of 
hypoxia showing the the SHRs responded to these interventions 
differently from the WKYs. 
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Hypertension, which affects a large portion of the 
world's population, continues to be a major risk factor in 
the premature development of serious cardiovascular disease. 
Diseases of the heart and of the blood vessels remain the 
leading cause of death in most western countries. 
Although hypertension is an extremely complex 
disease-state, long-term effective symptomatic control by 
drugs has been proven possible (Abrams, 1980; Freis , 1976; 
Gross, 1977; Saxena and Forsythe, 1976; Schmitt, 1977; 
Van Zweiten, 1975). The purpose of this study was to deduce 
the effects of selected drugs on human essential hyper-
tension by examining their effects on normotensive and hyper-
tensive laboratory rats. 
Development of Spontaneously 
Hypert·ensi ve Rat 
In an effort to develop a genetic animal model of 
human essential hypertension, Okamoto and Aoki examined the 
blood pressures of several hundred rats from the Wistar 
colony of the animal center at Kyoto University in 1963. 
The blood pressures in these rats averaged from 120 to 140 mm 
Hg as measured by tail-plethysmograph techniques without 
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anesthesia. One of the male rats examined exhibited a blood 
pressure reading of 145-175 mm Hg. A female rat with a 
blood pressure reading of 130-140 mm Hg was chosen for 
mating with this male rat. During the period 1959-1960, the 
male rat· maintained a sustained elevated blood pressure 
(higher than 150 mm Hg). Mating between the pair was repeated 
four times. 
The offspring of these matings consisted of 16 males 
and 20 females. All were fed a normal laboratory diet. Of 
these, 12 males and 6 females were found, at the age of 20 
weeks, to have sustained blood pressures above 150 mm Hg; 14 
males and 11 females were found to have similar sustained 
blood pressures at the age of 40 weeks. The offspring that 
exhibited hypertension for over 1 month were used for further 
brother-sister matings. Successive generations of hyper-
tensive animals were obtained by brother-sister matings of 
animals with sustained high blood pressure. Mean blood 
pressures increased with each succeeding generation, reach-
ing a plateau by about the sixth generation (F6 ). This 
process was continued until a colony of rats was produced 
in which blood pressures were uniformly more than 180 rom Hg 
by 20 weeks of age. 
The typical lesions (altered peripheral resistance, 
altered sensitivity to catecholamines, and altered handling 
of calcium by vascular smooth muscle and probably by cardiac 





hypertension were frequently observed in these rats, 
suggesting that the rats might be good models for the study 
of human disease. The animals were called Spontaneously 
Hypertensive Rats (SHRs) (Okamoto, 1962; Okamoto, 1969; 
Okamoto and Aoki, 1963). 
Successive brother-sister matings were continued in 
order to produce an inbred strain of SHR rats, which was 
obtained in October 1969 (Okamoto et al., 1972). This inbred 
strain was in the thirty-sixth generation in 1974. The 
colony of rats maintained at Kyoto University numbers some 
2,000 animals. Animals derived from this col ony have been 
introduced into about 200 institutions. 
Experience in many laboratories indicates that, for 
comparative purposes, only the parent--Wistar Kyoto normo-
tensive (WKY)--can s~rve as an adequate control for 
experimentation with SHRs . It should be emphasized, h6wever, 
that the SHR strain has been subjected to selection , which 
might have the effect of fixing genes that are still 
segregating in the WKY rat strain. 
Symptomatically , the disease entity of this animal 
model closely resembles human hypertension, even though the 
etiology of the disease may be different from that of most 
cases of human essential hypertension. Laboratory use of 
SHRs has been largely limited to studies relating to hyper-
tensive disorders, although several other abnormalities do 
exist in SHRs and others may become apparent in future 
studies. The use of the SHR as a model for genetic hyper-
tension is widely accepted, as illustrated in a review by 
Trippodo and Frohlich (1981). Some controversy regarding 
its use, however, still exists, as pointed out by McGiff 
and Quilley (1981). 
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SHR offers a unique model for studying the natural 
development of cardiac hypertrophy and its reversal by drug 
therapy (Sen et al., 1974). One such investigation led to 
the suggestion that factors other than arterial pressure are 
involved in the development of cardiac hypertrophy in hyper-
tension (Sen et al., 1974). The same study uncovered the 
different effects of antihypertensive drugs, including their 
effecti veness in the reversal of cardiac hypertrophy (Sen 
et al., 1974). Sen, Tarazi and Bumpus (1977) reported 
results that suggested that factors other than blood 
pressure control play a significant role in the reversal of 
cardiac hypertrophy by antihypertensive therapy. 
Antihypertensive Drugs 
An understanding of the sites and mechanisms of 
action of traditional antihypertensive agents, as well as of 
the pathophysiologic factors involved in the genesis of 
hypertension, may l ead to the development of more effica-
cious and less toxic drugs. This study was limited to a 
review of three types of antihypertensive interventions : 
(1) beta-adrenoceptor antagonists, (2) alpha-adrenoceptor 




The introduction of beta-blocking agents for the 
treatment of arrhythmias and angina (Dornhorst and Robinson, 
1962) was followed by the identification of the antihyperten-
sive properties of propranolol (Prichard and Gillam, 1964). 
Although early investigators exhibited some reservations 
regarding the significance of the antihypertensive effect 
(Richardson, Freund, and Gear, 1968; Paterson and Dollery, 
1966), a clear antihypertensive action was later confirmed 
by others (Hannsson, Malmcrona and Olander, 1972; Zacharias 
and Cowen, 1972). Thus the effectiveness of beta-blockers 
for a large portion of hypertensive patients has been 
established. 
The mechanism of the antihypertensive action of the 
beta-adrenoceptor blocking agent propranolol is largely 
unknown. What is known is that beta-adrenergic antagonists 
without intrinsic sympathomimetic activity, such as pro- · 
pranolol, decrease heart rate and cardiac output, prolong 
and decrease the velocity of mechanical systole and slightly 
decrease blood pressure in resting subjects (Helfant, Herman, 
and Gorlin, 1971; Robin et al., 1976). Peripheral resistance 
is increased as a result of compensatory sympathetic reflexes, 
and blood flow to all tissues e x cept the brain is reduced 
(Nies, Evans, and Shand, 1973). Beta-adrenergic blocking 
agents have minimal direct effects on the peripheral vascu-
lature, although propranolol causes a brief vasodilation 
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unrelated to beta-receptor blockade when injected intra-
arterially (Shanks, ·1967). The major effects of propranolol 
on the heart are absent in animals whose norepinephrine 
stores have been depleted (Shanks, 1966). 
Experience with the different beta-adrenoceptor 
antagonists provides strong evidence to indicate that their 
reduction in arterial blood pressure is primarily the result 
of a beta-adrenergic blockade. Beta blockade in the juxta-
glomerular apparatus of the kidney and in the heart, brain, 
postganglionic sympathetic nerve terminal, and vascular 
smooth muscle has been postulated as the primary mechanism 
at the target sites contributing to the antihypertensive 
effects of the beta blockers (Fitzgerald, 1975; Meier et al., 
1980; Saxena and Forsyth, 1976; Scriabine, 1979). 
The mechanism by which propranolol reduces non-
adrenaline release has been postulated by Adler-Graschvisky 
and Langer (1975) to be presynaptic beta-receptor blocks. 
Kalsner (1980), however, challenged this hypothesis. 
The spontaneously hypertensive rat is a commonly-
used model for studying pathogenic mechanisms and therapy 
of essential hypertension. A number of conflicting reports 
describe differing effects of propranolol in SHRs. Some 
authors reported that propranolol had no significant effect 
on blood pressure in spontaneously hypertensive rats, or 
even caused a slight rise (Forman and Mulrow, 1974; Levy, 
1976; Numao and Iriuchijima, 1974). Others found a 
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hypotensive action (Garvey and Ram, 1975; Sweet et al., 1976; 
Vavra, Tom, and Greslin, 1973). Smits, van Essen, and 
Struyker-Boudier (1980) showed that a lowering of blood 
pressure similar to that in hypertensive patients could be 
obtained if propranolol were delivered chronically, using 
osmotic minipumps, to the conscious unrestrained spontane-
ously hypertensive rat. 
Alpha-adrenoceptor Agonist: 
Clonidine 
The antihypertensive effect of clonidine was first 
discovered serendipitously in 1962 when Dr. M. Wolf adminis-
tered to himself and his secretary a few drops of a 0.3% 
solution (1-2 mgj of c l onidine . He immediately noted its 
sedative, bradycardiac and hypotensive e ffects as well as its 
decongestant properties (Graubner and Wolf, 1966; Kobinger, 
1978; Wolf and Morr, 1977). 
Clonidine was originally developed as a nasal 
decongestant, based on its chemical similarity with other 
imidazolines, which demonstrated vasoconstricting effects. 
It was by chance that Dr. Wolf discovered the pronounced 
blood pressure lowering and sedative properties of the drug. 
Since that discovery, clonidine has been widely used as an 
antihypertensive (Kobinger, 1978; Schmitt, 1977; Van Zwieten, 
1975). It has also been used successfully in mitigating 
severe withdrawal symptoms of opiate addicts (Gold, Redmond, 
and Kleber, 1978). 
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Clonidine is an alpha adrenergic receptor agonist 
that selectively stimulates postsynaptic alpha~adrenergic 
receptors in the depressor site of the vasomotor center of 
the medulla oblangata (Griep, 1978; Haeusler, 1974; Haeusler, 
Finch, and Thoenen, 1972; Henning, 1975; Kosman, 1975; 
Pettinger, 1975; Schmitt, 1969) in the region of the nucleus 
of the solitary tract (NTS) or locus coerculeus (Cedarbaum 
and Aghajanian, 1977; Gold, Redmond, and Kleber, 1978; 
Henning, 1975; Kobinger, 1978; Svensson, Bunny, and Agha-
janian, 1975). Activation of these central alpha-adrenergic 
receptors diminishes the efferent sympathetic neuronal 
vasoconstrictor tone to the heart, kidneys and peripheral 
vasculature, causing vasodilation and lowering blood 
pressure (Griep, 1978; Haeusler, 1974; Haeusler, Finch, and 
Thoenen, 1972; Hoobler and Kashina, 1977; Kosman, 1975; 
Pettinger, 1975; Schmitt, 1969). 
Although clonidine stimulates the postsynaptic 
alpha-adrenergic receptors, it actually has both pregangli-
onic and postganglionic alpha-adrenergic agonist-properties 
with variable potency in different organs (Kobinger, 1978). 
Clonidine may also influence blood pressure through alpha-
adrenergic receptors in suprabulbar structures such as the 
hypothalamus (Kobinger, 1978). 
The reduced sympathetic activity associated with 
clonidine is correlated with a decrease in plasma and 
urinary catecholamines, especially norepinephrine (Hokfelt, 
Hedeland,and Dymling, 1970; Whitsett, Chrysant,and Dillard, 
1978). 
Furthermore, it has been shown that small initial 
doses of clonidine lowers blood pressure. As the dose is 
increased, the blood pressure becomes refractory to the 
action of the drug (Conolly et al., 1972). Clonidine 
(0.1mgkg-1 , orally) has been found to result in a marked 
fall in blood pressure in Spontaneously Hypertensive Rats 
(Dadkar, Aroskar, and Dohadwalla, 1979). 
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Onesti, Schwartz, and Kim (1969 and 1971) found that 
acute oral administration of clonidine consistently reduced 
blood pressure and cardiac output in patients in a supine 
position. The reduction in cardiac output was attributed to 
a decrease in both heart rate and stroke volume, and no 
consistent changes in total peripheral resista~ce were found 
in patients in a supine position. However, oral administra-
tion to patients in an upright position caused a significant 
reduction in total peripheral resistance. Brod, Horbach, 
and Just (1972); McRaven, Kroetz, and Kioschos (1971); 
Muir, Burton, and Lawrie (1969) and Vorburger, Butikofer, 
and Reubi (1968) reported similar hemodynamic effects after 
acute administration of clonidine. 
Alpha-adrenoceptor Agonist: 
Alpha-methyldopa 
Alpha-methyldopa was shown to be an effective 
inhibitor of L-aromatic amino acid (dopa) decarboxylase by 
10 
Sourkes (1954) but it did not attract major attention until 
its hypotensive properties were noted during studies of 
aromatic acid metabolism in man (Oates et al., 1960). It 
has since come to be one of the major agents used in the 
treatment of essential hypertension. 
The mechanism of action of the drug in lowering blood 
pressure has been the subject of much investigation and some 
controversy (Henning, 1969: Muscholl, 1966; Stone and Porter, 
1966). The discovery of the presence of alpha-methyldopamine 
and alpha-methylnoradrenaline, metabolic products of alpha-
methyldopa, in the brains and hearts of mice treated with 
alpha-methyldopa (Carlsson and Lindqvist, 1962) was followed 
by the report that alpha-methyldopa and its metabolic 
products restored responses to sympathetic nerve stimulation 
in animals depleted of neuronal noradrenaline by reserpine 
(Day and Rand, 1963, 1964). The later workers suggested 
that in patients receiving alpha-methyldopa, alpha-
methylnoradrenaline formed by decarboxylation and beta-
hydroxylation might assume the transmitter function of 
noradrenaline. Since alpha-methylnoradrenaline was shown 
to possess weaker sympathominetic properties than noradrena-
line (Day and Rand, 1964) the "false transmitter" would lead 
to a partial sympathetic nerve blockade which might account 
for the symptoms of partial sympathetic impairment reported 
clinically (Bayliss and Harvey-Smith, 1962; Dollery and 
Harington, 1962). 
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The false transmitter hypothesis was supported by 
the demonstration of alpha-methylnoradrenaline release 
from sympathetic nerve after alpha-methyldopa pretreatment 
(Muscholl and Maitre, 1963) and by a report that inhibition 
of dopa decarboxylase abolished the antihypertensive effect 
of alpha-methyldopa (Davis et al., 1963). The antihyper-
tensive action of alpha-methyldopa has been variously 
attributed to the false transmitter hypothesis and the 
alpha-agonist property (Dollery and Bulpitt, 1975; Henning, 
1975; Kobinger, 1978). 
Alpha-methyldopa causes progressive reductions in 
blood pressure and heart rate. The decrease in blood 
pressure has been reported to be due to decreases in cardicac 
output, peripheral resistance, or both (Lund-Johansen, 1972). 
Alpha-methyldopa has been shown to decrease blood 
pressure in rats (Day, Roach, and Whiting, 1973; Filczewski 
and Boqucka, 1979). 
Ca++_Antagonist-Vasodilators: 
Verapamil 
One of the most exciting and interesting of the 
vasodilator type of antihypertensives is the calcium 
antagonist. The prototypes of this class of vasodilators 
are the chemically dissimilar compounds verapamil, diltiazem, 
and nifedipine. They appear to differ in certain aspects of 
pharmacologic profile; e.g., verapamil has a greater effect 
on myocardial AV conduction than nifedipine, whereas 
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nifedipine appears to have a greater blood pressure lowering 
action. 
Verapamil, a synthetic papaverine derivative, was 
first introduced as a smooth muscle relaxant with potent 
peripheral as well as coronary vasodilator properties in 
laboratory animals (Hass and Hartfelder, 1962; Melville and 
Benfey, 1965; Melville, Shister, and Hug, 1964; Nayler et al., 
1968) and in humans (Luebs et al., 1966; Mignault, 1966). 
Verapamil has been used for many years in the treatment of 
angina and various cardiac arrhythmias and is particularly 
useful in patients with airways disease. Several studies 
have shown verapamil to be as effective as beta blockers in 
the treatment of these conditions (I.ivesley et al., 1973; 
Sandler, Clayton, and Thornicroft, 1968). 
Although the primary therapeutic use of verapamil 
is as an antiarrhythmic and antianginal agent, some clinical 
studies have raised the possibility that verapamil may also 
be of value both in the management of acute hypertensive 
crises and in the treatment of essential hypertension 
(Lewis et al., 1979; Singh, Ellrodt, and Peter, 1978). 
Other findings indicate that the antihypertensive action of 
veraparnil is not sufficiently potent for the drug to be 
effective in the treatment of arterial hypertension without 
concurrent antihypertensive therapy (Pedersen, 1978). Oates, 
Stoker, and Stokes (1979) have shown verapamil to be a 
potent and effective hypotensive agent. 
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Veraparnil appears to exert its pharmacological 
effects primarily through calcium antagonism at the cell 
membrane of excitable tissues, impairing the entry of 
calcium ions into the cell during depolarization. This 
decreases the strength of contraction of cardiac and vascu-
lar smooth muscle, the latter effect producing peripheral 
vasodilation. Theoretically, this combination of peripheral 
vasodilation and reduction in cardiac contraction should 
produce a decline in blood pressure. Following intravenous 
injection, varaparnil has been demonstrated to cause hypo-
tension in both normal and hypertensive patients (Brittinger 
et al., 1970). A hypotensive effect has been noted in some 
angina studies where larger doses of the drug were used 
(Livesley et al ., 1973; Sandler, clayton, and Thornicroft, 
1968). 
Isolated Cardiac Muscle 
Papillary muscles from either the right or left 
ventricle are often used for studying the effects of drugs 
or other interventions on cardiac muscle mechanics. 
Isolated papillary muscle has been shown to be a represen-
tative model of the intact myocardium (Sonnenblick, 1962; 
Sonnenblick, Braunwald, and Morrow, 1965). Since Cattel 
and Gold's work in 1938 , isolated cardiac muscle has been 
used in experiments. Muscle mechanics were described first 
by A. v. Hill, the recipient of the 1923 Nobel Prize for 
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physiology and medicine for skeletal muscle. He described 
the "active state" (1938) and showed that it had intensity 
and duration (Hill, 1949, 1953). The intensity of the 
active state refers to the instantaneous rate of force 
development and is proportional to the maximal value of the 
first derivative of tension (dT/dt) . The duration of the 
active state is the amount of time it takes for the muscle 
to develop its maximal tension; therefore, it is related to 
the time to peak tension (TPT) . Application of the princi-
ples of skeletal muscle mechanics to the analysis of 
cardiac muscle performance began in 1959 with studies of 
Abbott and Mommaerts and later those of Sonnenblick (1964) 
and Brady (1967). 
The difference in skeletal muscle and cardiac muscle 
is that cardiac muscle must be prestretched and this elicits 
resting tension. There is a length (Lmax) of which maximum 
developed tension occurs; stretching beyond this length 
overstretches the muscle and results in a decline in devel-
oped tension. As resting length is increased, resting 
tension also increases. This increased force seen with 
increased initial length characterizes the Frank-Starling 
principle (Frank, 1895; Starling, 1918) derived initially 
in the intact heart. This phenomenon is known as stress 
relaxation. In the heart muscle a second general principle 
is also observed which does not generally obtain in 
skeletal muscle, namely changing "contractility." In the 
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isometric contraction, a change in contractility, induced 
by an inotropic intervention, is characterized by a change 
in the rate of tension development (dT/dt) from any initial 
length. The increase in dT/dt is usually, but not always, 
accompanied by an increase in developed tension (Sonnenblick, 
1962). 
Inotropic Agents 
Interventions that increase dT/dt are termed 
positive inotropic agents, .while those that depress dT/ dt 
are known as negative inotropic agents. 
Calcium 
Calcium is a positive inotropic agent, and calcium 
ions are intimately involved in the contraction of cardiac 
muscle. Calcium transport by the sarcoplasmic reticulum is 
a major mechanism by which intramyocardial levels of calcium 
and, thereby, tension development are modulated (Ebashi, 
Endo, and Ohtsuki, 1971). Participation of the sarcoplasmic 
reticulum in such regulatory processes depends on its 
ability to sequester calcium by an energy consuming process 
and, as a consequence, promote relaxation of myofibrils 
(Weber and Murray, 1973). In addition, the sarcoplasmic 
reticulum may serve as an intrace llular source of "activa-
tor" calcium, the release of which turns on the contractile 
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machinery following cardiac cell membrane depolarization. 
Changes in the capacity of sarcoplasmic reticulum to 
sequester calcium efficiently would, therefore, be expected 
to have an important impact on the contractile performance 
of the heart. 
Limas and Cohn (1977), found that sarcoplasmic 
reticula of spontaneously hypertensive rats exhibited 
depressed calcium uptake and binding. Aoki et al. (1974a) 
also found that sarcoplasmic reticula from hypertensive 
rat hearts showed low calcium binding capacity, and they 
concluded that this could induce contracture in hyperten-
sive cardiac muscle. Heller (1977), using the papillary 
muscle, observed accentuated aftercontractions without 
st~mulus in SHRs, suggesting decreased resequestration of 
calcium by the sarcoplasmic reticulum. This s uggestion 
was supported by Hamre ll and Alpert (1976), who used an 
isolated papillary muscle preparation and found that 
muscles from hypertensive rat hearts took a longer time 
for isometric relaxation than did muscles from normoten-
sive rat hearts; this indicates a decreased rate of calcium 
resequestration. 
Acidosis 
The negative inotropic effect of acidosis on 
cardiac muscle has been frequently demonstrated both in 
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vivo and in vitro since the first report by Klug in 1879 
and the detailed study of Smith in 1956. Since then, 
intracellular acidosis has been regarded as of major 
clinical importance as a cause of reduced cardiac function 
both in ischemia and heart failure (Katz and Hecht, 1969; 
Schwartz et al., 1973). 
The mechanism of altered myocardial contractility 
in acidosis has not been fully elucidated, but many sites 
of action for H+ have been considered. Katz and Hecht 
(1969); Fuchs, Reddy, and Briggs (1970); and Nakamuru and 
Schwartz (1970) postulated that, at low pH, excess hydrogen 
ions (H+) compete with calcium ions (ca++) for binding sites 
to the myocardial protein troponin and increase the binding 
of calcium ions (ca++) to the sarcoplasmic reticulum. This 
competition decreases the number of binding sites on tropo-
nin available for ca++ at a lowered pH, thus decreasing the 
amount of stored ca++ available for release upon excitation. 
The dependence of the heart on extracellular ca++ for 
++ + contraction supports the theory that Ca -H interaction 
accounts for the decline in ventricular performance (con-
tractility) during acidosis. 
Hypoxia and Reoxygenation 
The effects of hypoxia on papillary muscle prepara-
tions have been studied in some detail. Hypoxia induces a 
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reduction in, or even loss of, the contractile state 
(Bing, Brooks, and Messer, 1973; Buccino et al., 1967; 
Greene and Weisfeldt, 1974; Kent et al., 1972; Lee et al., 
1961; Tyberg, Parmley, and Sonnenblick, 1969; Winbury, 1956). 
Both the intensity and duration of the active state are 
diminished, since both the rate of tension development and 
time to peak tension decline (Buccino et al., 1967; Nakhjavan 
et al., 1971; Tyberg et al., 1970). Most papillary muscle 
preparations are made hypoxic with a gas mixture of 95 % 
nitrogen and 5% carbon dioxide or with a mixture of 85% 
nitrogen and 15% carbon dioxide. Under these conditions, 
negative inotropic effects are seen with the first 5 minutes 
of hypoxia (Lee et al., 1961; Nakhjavan et al., 1971; 
Tyberg et al., 1970). 
When muscles are reoxygenated after an hypoxic 
period, a marked prolongation of time to peak tension and 
relaxation is observed soon after reoxygenation is begun, 
which then gradually shortens as force development incre ases 
later in the reoxygenation period (Bing, Brooks, and Messer, 
1968; Nakhjavan et al., 1971; Tyberg et al., 1970). Taubert, 
Bufalino, and Amico (1980) found that, at the end of the 
first hour of hypoxia, the maximum rate of tension develop-
ment was depressed by 50-60% in all of the four subgroups 
studied. At the peak inotropic effect of increased Ca++, 
however, differences in muscle performance were noted. When 
++ Ca was raised from 1.0 to 2.5mM, dT/dt was increased by 
81% in the SHRs and by 47% in WKYs. These increases were 
significantly different from each other. ++ When Ca was 
elevated from 2.5 to 5.0mM, dT/dt was increased by 25% in 
the SHRs but did not change in WKYs. This showed that 
hypertensive and normotensive cardiac muscle respond simi-
larly to the negative effects of hypoxia, but differ in 
their responses to the addition of extracellular calcium 
during this period. 
Hypoxia and reoxygenation can be associated with 
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calcium overload within the cardiac cell, which can lead to 
decline of mechanical function. Hypoxia at l ow pH, however, 
can prevent much of this calcium overload. The phenomenon 
of calcium overload during hypoxia and reoxygenation has not 
been examined in hypertensive cardiac muscle, but Lakatta , 
Nayler, and Poole-Wilson (1979) measured mechanical function 
and calcium accumulation in isolated normotensive muscle. 
They found that when hypoxia was induced at a low pH (6.8), 
subsequent reoxygenation at normal pH was not associated 
with calcium overload or the development of contracture. 
The greatest calcium overload occurred in the reoxygenation 
period after hypoxia at normal pH. 
Isoproterenol 
Isoproterenol is the most active of the sympatho-
mimetic amines. It acts almost exclusive ly on beta receptors 
by virtue of N-alkyl substitution and has essentially no 
action on alpha receptors. Isoprote r e nol was f irst studied 
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by Konzett in 1940 and has since been the subject of exten-
sive animal and clinical research. 
Isoproterenol has a positive inotropic effect in 
mammalian myocardium. It is generally believed that the 
positive inotropic actions of isoproterenol result from an 
increase in calcium influx via the slow inward current 
coupled with an increase in the ability of intracellular 
organelles, notably the sarcoplasmic reticula, to handle 
the increased calcium load. Thus, not only is more calcium 
admitted into the cell during each contraction cycle, but a 
greater amount of calcium in releasable intracellular stores 
is available for contraction (Schol z , 1980). This effect of 
isoprotereno l on calcium appears to be mediated by cyclic 
adenosine 3'5' monophosphate (cyclic AMP) (Kelly and Corbin, 
1977; Robinson et al., 1965). Most of the effects of cyclic 
AMP in mammalian tissues are modulated by changes in the 
activity of cyclic AMP--dependent prot ein kinase. Beta 
receptor blockade, on the other hand, produces metabolic 
rearrangements in myocardial cells and also decreases pene-
tration of ionized calcium into cytoplasm. 
Statement of Purpose 
This study was undertaken in order to determine: 
1. What is the performance of isolated cardiac 
muscle removed from SHR and WKY hearts? Muscle mechanics 
were evaluated (a) during acidosis and hypoxia at different 
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extracellular calcium concentrations; (b) after addition of 
isoproterenol to the muscle, both in the presence and 
absence of propranolol; and (c) in SHRs after chronic 
antihypertensive therapy. 
2. Which drugs work effectively in chronically 
decreasing blood pressure and which mode of administration 
(that is, pump, drug in drinking water, or intraperitoneal 
administration) is most effective? 
3. Does cardiac hypertrophy disappear after chronic 
antihypertensive treatment? 
Study Design 
This study was subdivided into three major parts. 
First, comparisons were made of the muscle mechanics 
of SHRs and WKYs during acidosis and hypoxia at different 
extracellular calcium concentrations. Second, comparisons 
were made of the responses of papillary muscle from SHRs 
and WKYs to isoproterenol added both in the presence and in 
the absence of propranolol. Finally, an evaluation of 
chronic antihypertensive therapy in SHRs was made in order 
to determine which drugs work effectively and which mode of 
administration is most effective. Further, the animals 
whose blood pressures were significantly lowered for 6 weeks 
or longer were studied to see if hypertrophy disappeared and 
how their papillary muscle responded to acidosis and 
hypoxia. 
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The central aim of this study was to determine if 
SHRs respond differently from WKYs when extracellular 
calcium is increased from 1.0mM Ca++ to 2.5mM Ca++ and then 
made hypoxic. It was also to see if chronically treated 
rats respond more like the SHRs or WKYs. 
Other investigators (Aoki et al., 1974; Hamrell and 
Alpert, 1976; Heller, 1977; Limas and Cohn, 1977) have all 
shown that the SHRs handle calcium differently from WKYs. 
They showed that there is a decreased resequestration of 
calcium by the sarcoplasmic reticulum of the SHRs. Heller 
(1978) showed that spontaneous after-contractions occur 
more frequently and with greater amplitude following paired 
pulse stimulations in SHRs than in WKYs. Doca-treated rats 
did not demonstrate exaggerated after-contractions when 
compared to WKYs. Taubert et al. (1980) have demonstrated 
that when extracellular calcium was increased during hypoxia, 
the SHRs responded differently from WKYs. 
Chapter 2 
MATERIALS AND METHODS 
All experiments were carried out on two types of 
adult male rats (4-6 months of age) weighing 250 gms to 450 
gms. One type was the spontaneously hypertensive rat (SHR) 
from the Okamoto-Aoki strain. The second type was the age-
matched Wistar Kyoto (WKY) normotensive control. SHRs and 
WKYs were maintained and bred in the U.O.P. vivarium. There 
were about three to four rats per cage on commercial rat 
chow and tap water. Breeding was by brother-sister mating. 
Rats were kept on 12 hours light-12 hours dark cycle. 
Chronic Antihypertensive Treatment 
The SHR population was divided into four groups, 
each of which was subjected to a different chronic anti-
hypertensive treatment. SHRs that were chronically treated 
are referred to as PRET (pretreated rats). 
Group 1: Propranolol 
Hydrochloride 
Three male SHR rats (250-450 gms) were placed under 
methohexital sodium anaesthesia (60 mg/kg i.v.) and an 
ALZET osmotic minipump (model 2002, Alza Corporation, Palo 
Alto, California) containing propranolol hydrochloride 
(Sigma) dissolved in water was implanted subcutaneously in 
the dorsal region via a small skin incision. This pump 
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provided a continuous infusion of 20 mg/kg/day. Amount of 
propranolol used was dependent on weight of the rat such 
that it received 10 mg/kg/day. The nominal pumping rate of 
the device was 0.55 u 1/hr. This guaranteed a constant flow 
during at least 14 days in vivo in rat subcutaneous tissue 
(product information, Alza Corporation). At the end of the 
fourteenth day of infusion, the minipumps were removed from 
the animals and new minipumps implanted. This procedure was 
repeated for two subsequent 14-day periods. 
In addition, rats in this group were given proprano-
lol hydrochloride (Sigma) in their drinking water (60 mg/ 
liter). 
Preliminary testing showed that neither route was 
effective in lowering blood pressure. 
Group 2: Alpha-Methyldopa 
Five male SHRs were treated with alpha-methyldopa 
(Merck, Sharp, and Dohme). The rats were injected with 
alpha-methyldopa (75 mg/kg i.p.) daily. Powdered alpha-
methyldopa (5 gm/liter) was also added to their drinking 
water. 
Group 3: Clonidine 
Hydrochloride 
Thirteen SHR rats were given clonidine hydrochloride 
(Boehringer Ingelheim) (0.6 mg/kg/day ) through ALZET osmotic 
minipumps implanted subcutaneously in their dorsal regions. 
The procedure was the same as that described for Group 1 • 
Eight of the 13 SHR rats were also given clonidine hydro-
chloride mixed in their drinking water (0.5 mg/50 cc). 
Group 4: Verapamil 
Seven SHR rats were treated with verapamil (Knoll 
Pharmaceutical). The verapamil was dissolved in their 
drinking water (40 mg/50 mL). All the rats in the four 
groups drank about 25-30 ml of water/day with or without 
drugs in it and this was the same for SHRs and WKYs. 
Blood Pressure Monitoring 
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Systolic blood pressure was measured in unanesthe-
sized rats by the plethysmographic tail cuff method (Bunag, 
1973; Williams, Harrison, and Grollman, 1939). Prior to 
measurement, each rat was restrained in a lucite container 
connected to a temperature control unit (Narco Biosystems, 
type MK IV) which was set at "5" (40°C on warmer) and 
allowed to warm up fo~ 10 or 15 minutes, for the purpose of 
increasing blood flow in the tail (Rand, Burton, and Ing, 
1965). A pressure cuff (E & M Instrument Company) was 
placed on the tail of the rat. The bulb sensor was held 
to the tail by tape approximately 3/8 inch wide, holding the 
sensor in a partially deflated condition. The pneumatic 
pulse transducer was connected to an electrosphygmograph 
(E & M Instrument Company, type ESG-300) which was, in turn, 
connected to the pressure cuff and a desk model Physiograph 
4-channel recorder (E & M Instrument Company, type D.t-1P-4A) . 
Figure 1. Rat blood pressure monitoring 
set up 
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The cuff was inflated; upon release of the pressure, blood 
flowed back into the tail. This blood flow set up pulsa-
tio ns which could be picked up by the pneumatic bulb, which 
transmitted it to the pneumatic pulse transducer. The 
signals from the pneumatic -pulse transducer passed through 
an amplification unit (Narco Biosystems) in the Physiograph. 
The unit was calibrated before each session of blood 
pressure recordings by setting the deflection of the tracing 
stylus to 2 . 5 em on the graph paper (Narco Biosystems) for 
every 100 mmHg pressure. A minimum of three pressure 
measurements were taken on each rat, · at 2-minute intervals 
in a room with quiet environment . 
Papillary Muscle 
Rats were anesthesized with sodium pentobarbital 
(30 mg/kg i.p.) and papillary muscles taken from the left 
or right ventricles . Hearts were disse cted free and opened , 
and a suitable muscle rapidly removed by clipping it free at 
each end. The muscles were mounted vertically between two 
spring-loa ded clips , and a tension transducer (Statham UC 
2) attached to the top clip. The immobility of the clips 
allowed the papillary muscles to contract isometrically . 
The platform holding the top clip was connected to a micro-
meter, facilitating manual l e ngth adjustments. 
A 20 ml volume bath containing a Krebs-Ringer 
bicarbonate buffer solution was prepared. A gas mixture 
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Figure 2. Papillary muscle bath 
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of 95% o2 and 5% co2 was used to aerate the solution. After 
equilibration with co2 , a pH of 7.4 was recorded. Tempera-
ture was maintained constant at 30°C by surrounding the bath 
with a sleeve connected to a Haake circulating pump. The 
muscles were lowered into this bath and stimulated, at a 
rate of 12/min., by a Grass stimulator (model S-88) with 
platinum electrodes placed parallel to, but not touching, 
the muscle. Voltage used was threshold +20%, and duration 
averaged 10 ms. 
After a 1-hour stabilization period, Lmax (muscle 
length at which maximal developed tension occurred) was set. 
X Lmax for all muscles used in these studies was 4.68 ± 
0.229 mm. Control measurements were then made and individual 
experiments begun. At the conclusion of the experiments, 
the muscles were weighed and the cross-sectional areas 
([muscle weight/muscle length]/[density of water]) X CSA = 
0.99 ± 0.051 mm2 • Measurements taken included resting 
tension {RT), developed tension {DT), maximal rate of 
tension development {+dT/dt), maximal rate of tension 
decline {-dT/dt), time to peak tension (TPT), time to half 
relaxation {RT~ ), and time to maximal relaxation {TPR). 
All data except TPT, RT~ , and TPR were divided by cross-
sectional area for normalization of data. The control 
measurements taken refer to zero time immediately prior 
to beginning of intervention. Control values are taken to 
be 100% and subsequent minutes show change of percentage. 
Individual Protocols 
Addition of Isoproterenol Before 
and After Propranolol 
After muscles stabilized and control measurements 
were taken, 10-6M isoproterenol was added directly to the 
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bath via a microliter pipette. Data were then collected for 
15 minutes at 5-minute intervals. At the end of this 15-
minute period, 10-6M propranolol was added directly to the 
bath via a microliter pipette. Data were collected over a 
10-minute period. Following this the bath was washed 
thoroughly and 10-6M isoproterenol again added to the bath 
and data taken at 1-minute, 5-minute, and 1+-minute inter-
vals . 
A total of 13 muscles were treated with propranolol 
and 12 muscles treated with isoproterenol, while 14 muscles 
were treated with only isoproterenol. 
Acidosis and Change in 
Extracellular Calcium 
After the muscles stabilized in a buffer containing 
1.0mM Ca++, control readings were taken. Acidosis was 
induced by changing the aerating gas mixture from 95% 
o2 - 5% co 2 to 85% o2 - 15 % co2 . This lowered the pH of 
the muscle bath from 7.4 to approximately 6.9. The read-
ings were taken every 5 minutes for 1 hour. At the end of 
the hour, extracellular calcium was increased from 1 . 0 to 
2.5mM Ca++ and maintained at this level for 30 minutes, 
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which was sufficient time for peak inotropic effect to have 
been reached. 
Hypoxia and Reoxygenation 
The muscle was made hypoxic while maintaining 
++ acidosis and Ca level of 2.5mM by changing the gas mixture 
from 85% o2 - 15% co2 to 85% N2 - 15% co2 . The hypoxia 
lasted for 1 hour. During this hour, data were collected. 
At the end of this period, acidosis was terminated by 
changing the gas mixture to 95% o2 - 5% co2 (reoxygenation) . 
Data were also collected at this point. 
Statistics 
Comparisons of blood pressure before and after 
treatment were considered statistically significant at 
p 2 0.05 level using the paired t-test. Contractility 
changes of the papillary muscle due to isoproterenol, pro-
pranolol, acidosis, hypoxia and reoxygenation were compared 
using the paired t-test and were considered statistically 
significant at p ~ 0 .+5 level. Comparisons among groups of 
muscles were made using the groups t-test and a significance 
of p _::: 0.05. Data were compared using either the grouped or 
the paired t-test, as appropriate, and results considered 
significant at p ~ 0. 05. 
Chapter 3 
RESULTS 
Effectiveness of Various Methods 
of Administration 
The ALZET osmotic minipump was not effective with 
all the drugs used. Propranolol administered through t he 
minipump resulted in variable results in the three rats 
(see Table 1). The mean blood pressure reading decreased 
for a few weeks, then rose. 
While clonidine administered through the ALZET 
osmotic minipump did result in decreased blood pressure, 
all the rats with the clonidine pump died at some time 
while being warmed for blood pressure monitoring. Prior 
to death, they were observed to be "frothing" from the 
nose and mouth. Autopsies revealed that these rats had 
hemorrhage in their lungs. 
Alpha-methyldopa could not be administered through 
the minipump because the dose of alpha-methyldopa required 
for the treatment of hypertension was too high to be 
dissolved in the 228.0 ~£ water used in the pump. The pump 
was not used with verapamil because verapamil was n ot 
soluble enough in a carrier to be diluted to 228.0 ~ £ . 
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Effect of Clonid ine, Alpha-Methyldopa, Verapamil and Propranolol on the 
Blood Pr essure of Spontaneous l y Hyper t e nsive Rats 
0 1 2 3 4 5 6 7 8 9 
Mean 198 . 8 167.5 165.0 155 .0 155 . 7 140.0 148.0 156.7 160.0a 155.0b 
± SEM 7.9 8.0 5.3 7 . 1 3 . 5 6 . 8 11.6 20.3 5.8 15 . 0 
Mean 194.4 165.6 152. 4 153.8 166 .0 162 . 5 164 . 3 167.5 1 50 . 0b 180.0b 
:t SEM 4. 1 4.5 13.6 10 . 6 5.4 7 .5 10 . 9 11 . 1 10 . 0 10.0 
Mean 180.0 168.6 159. 3 145 .7 150 . 0 14 7 . 1 142.9 
:t SEM 3.8 9.4 6 . 6 6.1 7 . 2 9 .9 9.4 
Mean 188.3 160.0 16 3.3 160.0 158.3 183 . 3 173 .3 140 . 0c 140.0c 140.0c 
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The osmotic minipump was a good vehicle for admin-
istration of some drugs because it maintained a constant 
daily dose and it eliminated the problems involved in 
handling the rat every day. One drawback encountered was 
the small capacity of the pump, which eliminated some drugs. 
Drinking Water 
Mixing the drugs in drinking water was effective for 
some drugs but not for others. Propranolol administered 
only in the drinking water could not lower blood pressure 
more than 10%. Very little decrease in blood pressure was 
obtained when alpha-methyldopa was mixed in the drinking 
water. On the other hand, both clonidine and verapamil 
mixed in drinking water resulted in significant decreases 
in blood pressure (see Figure 7). 
Injection 
Rats given alpha-methyldopa as an anti-hypertensive 
treatment were the only subjects treated by intraparitoneal 
injection. This method of delivering the drug was effective, 
but it increased the chances of infection. 
Magnitude of Blood Pressure Decrease 
As shown in Table 1 and Figure 3, only one of the 
three rats treated with propranolol evidenced decreased 
blood pressure. In this rat, propranolol (administered 
through a combination of pump and drinking water) caused a 
Figure 3. The effect of propranolol on blood 
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22.2% decrease in blood pressure at the end of 12 weeks of 
treatment. In the other two rats, blood pressures fluctu-
ated during the chronic treatment and they died by the end 
of the sixth week. 
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Table 1 and Figure 4 show the effects of clonidine 
(administered in drinking water), Table 1 and Figure 5 show 
the effects of alpha-methyldopa (administered through 
injection and drinking water) and Table 1 and Figure 6 show 
the effects of veraparni l (in drinking water) on the b lood 
pressures of spontaneously hypertensive rats. The eight 
rats treated with clonidine displayed a 25.5% decrease in 
blood pressure at the e nd of the s ixth week. Five of these 
rats were used for papillary muscle studies at the end of 
the seventh week and the two died later. 
Alpha-methyldopa caused a 15.5% decrease in blood 
pressure in the rats at the end of the sixth week. Two rats 
on the alpha-methyldopa till the twelfth week showed a 28% 
decrease in blood pressure, as seen in Figure 5. Three 
rats died by the end of the seventh week. 
Veraparnil treatment resulted in a 20.6% decrease in 
blood pressure in all seven rats by the sixth week and was 
terminated here. Four of the rats were used for studies. 
Treatment with clonidine, with alpha-methyldopa , 
and with veraparnil yielded significant decreases in blood 
pressure by the end of the sixth week (Figure 7). 
Figure 4. This figure shows the mean values 
(± standard error) of the blood pressure resulting 
from the chronic treatment of SHRs with clonidine 
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Figure 5. This figure shows the mean values 
(± standard error) of blood pressure resulting from 
the antihypertensive effect of chronic treatment by 
alpha-methyldopa on spontaneously hypertensive rats 
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Figure 6. This figure shows the mean values 
(± standard error) of blood pressure resulting from 
antihypertensive effect of chronic treatment by 
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Figure 7. Mean blood pressure readings of 
spontaneously hypertensive rats before and after 
treatment · 
p values are results of paired students t-test 
comparing blood pressures in the same rat before and 

























































Effect of Chronic Antihypertensive 
Treatment on Hypertrophy 
Table 2 shows the heart to body ratios of SHR, WKY 
and pretreated rats. The heart to body weight ratio was 
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significantly greater in the SHR than WKY (p < 0.01). Over-
all, the heart to body ratio of the rats that were chroni-
cally treated with antihypertensives was 3.37 ~ 0.26. 
Papillary Muscle Studies 
In the papillary muscle studies the mean control 
data for all SHRs RT = 1.01; DT = 2.97; +dT/dt = 34 .2; -dT/dt= 
20.4; TPT = 172.9; RT~ = 101.3 and TPR = 279.7 were equal to 
those for the WKYs, RT = 0.84; DT = 2 .88; +dT/dt = 34.5; 
-dT/dt = 20.5; TPT = 152.8; RT~ = 96.3; and TPR = 273. 
Response to Isoproterenol 
in Presence or Absence 
of Propranolol 
One part of the study examined the effect of isopro-
terenol (10-6mM) in the absence of propranolol (10- 6mM) on 
cardiac muscle mechanics. Table 3 shows normalized data, 
while Table 4 expresses that data as percentage of control. 
One minute after isoproterenol addition, developed tension 
was significantly lower than control for both SHR (p < 0. 01) 
by 0.49 and WKY (p< 0.05) by 0.42. After 10 minutes, only 
the SHR was significantly lower than control (p < 0.05) by 
0.14. A significant decrease was seen 15 minutes after 
Table 2 








n Body wt. (gm) 
7 352.2 ± 23.0 
7 364.7 ± 30.6 
2 302.4 ± 7.5 
2 267.2 ± 67.9 
1 223.3 
+ Data are mean - standard error 
;';p < 0. 01 
Heart wt. (gm) Ratio (X1o-3) 
0.878 ~ 0 .067 2 . 50 ± 0 . 11 ·k 
1.269 ± 0.143 3.44 ± 0 .1 2* 
1.048 ± 0.172 3.45 :t 0.48 
0.809 :!: 0 .050 3 . 19 ± 0 . 62 




The Effec ts of Isoproterenol on Papillary Muscle Mechanics 
Maximal Rate Maximal Rate Time to 
Resting Developed of Tension of Tension Time to Time to Half Maximal 
Time Rat. Tension Tension Development Decline Peak Tension Relaxation Relaxation 
(min) Type (g/mm2) (gjmm2) (gjmm2sec) (g/mm2sec) (msec) (msec) (msec) 
CONTROL WI<Y 0 . 95 + 0 . 09 3 . 66 + 0.45 45.80 + 5.62 27.64 + 3.19 156 . 67 + 3.54 94 . 44 + 3.67 336.67 + 11 . 96 
SHR 1.14 + 0.13 4 . 59 + 0.89 54.68 + 10.02 29 . 36 + 4.57 172. 50 + 2. 50 104.17 + 10.03 354.17 + 15.02 - -
1 WKY 0.92 + 0 . 09 3 . 24 + 0.43** 46 . 26 + 6.47 25 . 54 + 3 . 69 145.63 + 3.19 93 . 13 + 3.12 331.25 ±. 6.25 - -
SHR 1.14 + 0.13 4.10 + 0.81** 54.50 + 9.59 26.03 + 3 . 88 162.50 + 5.28 90 . 00 + 11.03 351 . 67 + 15 . 63 - - - -
5 WKY 0.94 + 0.09 3.60 + 0.44 48.47 + 5.52 27.94 + 3.34 147 . 78 + 2 . 90 86.67 + 3 . 91 307.7 8 + 6 . 88 
SHR 1.12 + 0.13 4.41 + 0.86 56.20 + 9.96 29 . 64 + 4 . 60 161.67 + 5.27 93.33 + 6.01 337.50 + 17 . 97 
10 WI<Y 0.94 + 0.09 3 . 52 + 0.43 46 . 84 + 5.50 28 . 70 + 3 . 83 147 . 78 + 2 . 90 86.11 + 5 . 39 308.33 + 11.02 
SHR 1. 10 + 0 . 13 4 . 45 + 0.88** 54 . 58 + 9.88 30 . 15 + 4.65 162.50 + 4 . 23 96.67 + 7.82 330.83 + 14.16 - -
15 WKY 0.97 + 0.11 3.31 + 0 . 41* 44.39 + 5.48 27.36 + 3.61 150.00 + 2.76 84.44 + 5.68 296.88 + 15 . 97* 
SHR 1.10 + 0.13 4.00 + 0 . 82** 51.13 + 9.35**29.51 + 4 . 54 167 . 50 + 3 . 82 89.17 + 6.51 326 . 67 + 10.14 - -
Data are mean ! standard error 
(SHR, n = 6; WKY, n = 8) 
>'<p < 0. 01 l1l 
>h'<p < 0.05 0 
Table 4 
Percentage of Control Data of Papil l a r y Muscle Mechanics Due to Addition of Isoproterenol 
Maximal Rate Maximal Rate Time to 
Resting Developed of Tension of Tension Time to Time to Half Maxi mal 
Time Rat. Tension Tension Development Decline Peak Tension Relaxation Relaxation 
(min) Type (g/mm2) (g/mm2) (g/mm2sec) (gj mm2sec) (msec) (msec) (msec) 
1 WKY 99 . 10 + 0.9 93.51 + 1.9 103 . 06 + 2 . 4 94 .14 + 3 . 8 93 . 2 + 1. 3 100.0 + 3.3 101.4 + 3 . 3 
SHR 1 00.00 + 0 . 0 89.82 + 1.7 100.72 + 1. 6 88.83 + 2.3 94 . 2 + 2.7 85.8 + 5 . 3 99.6 + 3.5 
5 WKY 99 . 01 + 2 . 0 98.30 + 1.4 109.42 + 5.2 101.70 + 2.8 94.5 + 1.7 93.3 + 3.6 91.8 + 1.7 
SHR 98 . 22 + 1. a 96 . 88 + 1.9 103 . 70 + 2 . 2 100 . 88 + 2 . 3 93 . 7 + 2 . 7 91.3 + 4.1 95 . 8 + 5 . 2 
1 0 WKY 99 . 01 + 2.0 96 . 47 + 1.8 104.82 + 4 . 7 102.68 + 3 . 3 94 . 5 + 2 . 0 93 . 0 + 3 . 7 92.0 + 2.9 
SHR 96 . 80 + 2 . 0 96 . 35 + 1.8 100 . 35 + 2.1 102.82 + 1.3 94.3 + 2 . 7 94.0 + 3.8 93.7 + 3.2 
15 WKY 101.57 + 2.6 89.73 + 1.3 97 . 24 + 2 . 8 96.45 + 2.4 95.4 + 1.9 89.1 + 4 . 4 88 . 3 + 2.8 
SHR 96 . 80 + 2.0 87 . 52 + 3.8 93 . 57 + 1.4 100.82 + 1.6 97 . 2 + 2 . 5 97 . 2 + 4 . 4 92 . 7 + 2 . 8 
Data are mean ± standard error 
(SHR, n = 6; WKY, n = 8) 
\ • .Tl 
--" 
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addition of isoproterenol in both SHR (p < 0.05) by 0. 59 
and WKY ( p < 0. 01 ) by 0. 3 5 • 
The second part of the study examined the effect of 
the addition of 10-6mM isoproterenol in the presence of 
6 10- mM propranolol. Table 7 shows the mean normalized data 
and Table 8 gives the percent of control of the normalized 
data of papillary muscle mechanics in response to 
isoproterenol added 10 minutes after the addition of 
propranolol. One minute following the addition of isopro-
terenol, DT, +dT/dt and -dT/dt of the WKY were significantly 
higher than control (p <0.05) by 0.18, 1.31, and 1.03 
respectively. After 5 minutes, the +dT/dt of the WKY was 
significantly higher than control (p < 0.05) by 1. 60 and the 
-dT/dt of the WKY was significantly higher than control 
(p < 0.01) by 1. 55. Only the -dT/dt of WKY was signifi-
cantly higher than control (p < 0.05) by 1 .16 after 10 
minutes. 
Response to Propranolol 
Normalized data (Table 5) show that 1 minute after 
the addition of propranolol (10-6rnM) the DT of WKY and the 
SHR were significantly lower than the control (p < 0.05) by 
0.06 (WKY) and 0.09 (SHR). After 5 minutes, the DT of the 
WKY and SHR, the +dT/dt of only WKY, the -dT/dt of both 
WKY and SHR and the TPR of only SHR were significantly 



















o. 60 ± 0.11 
0 . 85 ± 0.11 




0. 57 : 0.10 
0.86 ± 0.12 
Table 5 




1. 50 ± 0. 36 





15.48 ± 3.73 
25.76 ± 3.79 
1.44: 0 . 34** 14.68 ± 3 .43 
2.09 ± 0.32** 25.31 ± 3.82 
1.19 ± 0.67** 13 .85 ± 3.31** 
1 .97:!: o.3o** 24.11 :!: 3.88 
0.91 ± 0.19 12.55 ± 3.00'b'< 





10.30 ± 2.13 
16.25:!: 2.18 
9. 80 : 2.10 
16.16 ± 2.10 
Time t o 
Peak Tension 
(msec) 
140.83 ± 13.56 
148.75: 4.88 
146.67 :!: 20.91 
140.00 ± 10.30 
9.18 ± 1.96** 150.00 ± 25.06 
15.34 ± 2.09** 148.12 ± 1.31 
7.88 ± 1 .58** 155 .00 ± 22.58 
12.99 ± 2.43 1 4 7 • so ± 1 • 6 4 
Data are mean ± standard error 
(SHR, n = 8; WKY, n = 6) 
>'<p < 0.01 
1d<p < 0 .05 
Time to Half 
Relaxation 
(msec) 
90.83 ± 6.11 
88 . 12 ± 6 . 61 
80.00 :!: 8.46 
97.50! 4.12 
85.83 ± 8.60 
88.75 ± 3.63 
80.83 ± 8.31 






213.75 ± 17.71 
210.83 ± 31.12 
213.12 ± 10.68 
215.00 ± 26.13 
193.12 ± 10.08+-'< 
143.33 ! 33.20 








Percentage of Control Data of Papillary Muscle Mechanics Due to Addition of Propranolol 
Maximal Rate Maximal Rate 
Resting Developed of Tension of Tension Time to Time to Half 
Rat . Tension Tension De ve l of.men t Decline Peak Te nsion Relaxation 
Type (g/nun2) (g/nun2) (g/nun sec) (g/mm2sec) (msec) (msec) 
WKY 103 . 0 ±" 1 .9 96.7 ± 1.1 96.1 ± 1. 6 95.0 : 5.0 102.7 ± 6.7 87.3 : 4.6 
SHR 98.9: 1.1 96.6 :!: 1.2 98.2:!: 1.3 99.6 ::!: 3.8 93.3 ± 5.2 113.7 ± 7.2 
WKY 101.3 :!: 4.55 79.7:!: 3.8 90.7:!: 2 . 4 88 .1 + 4.5 104 . 4 : 9.3 94.5 :!: 5.9 
SHR 98.9 :!: 1.10 91.9::!: 2.8 90.4 ± 4.9 93.2 ::!: 3.2 100.3 :!: 3.3 103.2 ± 6.0 
WKY 97.7:!: 3.4 72.8 :!: 6.2 80.7:!: 2.4 77 . 4 :!: 4.3 109.3 :!: 8.4 88.8 ± 5.6 
SHR 99.8 : 1 . 5 74 . 4 :!: 9.0 79.5 ± 9.6 77.3 ± 10.7 99 . 7 ± 2.5 93.3:!: 4.1 
Data are mean ± standard error 





94.1 :!: 5.4 
102.6 + 6.9 
97 .0 :!: 6.7 
91 . 9 :!: 3. 2 
92.4 :!: 5. 3 




Mean Values of the Effects of Isoproterenol on Papillary Muscle 
Mechanics After Addition of Propranolol 
Maximal R;;~te Maximal Rate Time to 
Resting Developed of Tension of Tension Time to Time to Half Maximal 
Time Rat. Tension Tension Develof.ment Decline Peak Tension Relaxation Relaxation 
(min) Type (g/mm2) (gjmm2) (g/mm sec) (g/mm2sec) (msec) (msec) (msec) 
Control WKY 0.56: 0 . 11 0.96 ± 0.18 12.07:!: 3.15 7.77:!: 1.63 150.83 : 20.91 77. so :!: 8 . 34 216.67 : 26.38 
SHR 0.96 ± 0.13 1.94 :!: 0.38 24.54 :!: 4.63 14.59 :!: 2.49 148.33 : 1. 67 84.17: 7.57 184.17:!: 13.56 
WKY 0 . 54:!: 0 . 11 1.14:!: 0 . 23'"''' 13 . 38:!: 3.24>'d< 8 . 80 :!: 1 . 8 1 >'<>'< 1 4 6 . 6 7 :!: 1 9 . 1 7 90.00 :t 10 .33 209.17:!: 19.46 
SHR 0.94:!: 0 . 12 1. 96 :!: o. 30 24.82 :!: 3 .9 14.99 :!: 1.68 148.33 :!: 1. 67 84.17:!: 6.38 175.83 :!: 8.20 
5 WKY 0. 52: 0.09 1.23:!: 0.30 13.67: 3.46>'<>'< 9.32:!: 1.99"' 143.33: 18.95 91.17: 9. 19 213.33 :!: 44.07 
SHR 0.91 ! 0. 12 1.92 :t 0.35 24.65 :!: 4.65 14 . 53 :!: 3.00 141.67 : 4. 01 81.67 :!: 3.80 176.67:!: 14.24 
10 WKY 0 . 53 : 0.10 1. 11 :!: 0. 28 12.72: 3.17 8 . 9 3 ± 1 . 80 * ''< 1 4 4 . 1 7 :!: 1 7 . 8 1 85 . 83 :!: 6.88 198.33:!: 21.47 
SHR 0 .92 ± 0.12 2.01 :!: 0. 26 25.97 ± 3.70 16.78:!: 1.71 145.83 :!: 3.74 83.33 :!: 3.80 183. 33 ! 13.01 
Data are mean ± standard error 
(SHR, n = 6; WKY, n = 6) 
'~P < 0.01 




Percentage of Control Data for the Effects of Isoprote renol Af ter Addition 
of Propranol o l o n Papillary Muscle Mechanics 
Maximal Rate Maxima l Rate 
Resting Developed of Tension o f Tension Time to Time to Hal f 
Time Rat. Tension Tension Deve l of.ment Decline Peak Tension Relaxation 
(min) Type (g /mm2) (g j mm2) (g/mm sec) (g / mm2sec) (msec) (msec) 
WKY 96.6 ± 2.2 117.8:!: 6.4 11 6 . 7 :!: 7. 8 11 4. 1 + 3 .4 9 7 . 7 ± 4.1 117 . 6 :: 8. 1 -
SHR 98 .9 ± 1.1 11 3. 1 ± 1 7. 5 107.0 ± 8 . 7 117. 8 :!: 21.5 100. 1 :: 1. 8 10 1. 4 :!: "4. 4 
5 WKY 94 . 9 :!: 2 . 3 122.4 :!: 9.5 111 . 8:: 3.9 121.9 :!: 3 . 4 95.2:!: 2.7 122.9 :!: 15 . 9 
SHR 95.8 ± 1.9 10 1 .9 :!: 3.8 99 . 7 ± 3.2 91.6 :!: 12.8 95.6 :!: 3.3 100 . 5:!: 8.5 
10 WKY 96 .3 :!: 2 . 4 108. 1 :t 11.21 104.9 :!: 5.2 11 5 . 1 + 4.9 96.3 :: 2 . 3 11 6.7 :!: 16.7 -
SHR 95.8:!: 1 .9 125 .5 :!: 31 . 0 117 . 1 :!: 16. 8 135 . 3 :!: 28.3 98 .4 :!: 3.0 104.7 :t 9.6 
Data are mean ± standard error 
(SHR, n = 6; WKY, n = 6) 
T ime to 
Maximal 
Re l axation 
(msec) 
98. 1 :!: 3.2 
97.6 :!: 7. 1 
95.7 :!: 9.3 
97.8 ± 6 . 0 
93.3 :: 6 .5 




was added to the bath, the developed tension of SHR was 
significantly lower than the control (p < 0.05) by o. 49, 
while the rate of tension development and -dT/dt of WKY 
were significantly lower than control (p < 0. 05) by 2. 9 3 
and 2.42 respectively. The data show that only the time 
to peak relaxation of SHR was significantly lower than the 
control p(0.01) by 33.12 after 10 minutes of intervention. 
In Table 6 the data in Table 5 are expressed as 
percentages of control. The table shows that 5 minutes 
after propranolol addition the developed tension of WKY 
was significantly lower than that of the SHR p(0.05) by 
12.2%. 
Response to Acidosis and 
Increase Extracellular 
Calcium (n = 21) 
In the first part of this protocol, muscles were 
subjected to acidosis for 1 hour. At the end of the hour, 
contractility of all groups of papillary muscles was 
significantly depressed when compared to their pre- acidotic 
controls (Figures 8 and 9). After 30 minutes of acidosis, 
contractility decreased by 29.0% (p < 0. 05) for the WKY, 
while for the SHR it remained the same as that of the 
control. After 60 minutes , SHR was significantly higher 
than WKY by 21% (p < 0.01) (Figure 9). Table 9 shows the 
normalized data of the effect of acidosis on papillary 
muscle mechanics while Table 10 expresses this data as 
percent control. Control data are mean parameters of 
53 
Figure 8. Effects of Acidosis, increased calcium, 
hypoxia and reoxygenation on the developed ten~ion of 
papillary muscles (SHR, n = 7; WKY = 7; PRET, n = 7) 
p values are results of grouped t-test comparing 
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Figure 9. Effects of Acidosis, increased calcium, 
hypoxia and reoxygenation on the maximum rate of tension 
development of papillary muscles (SHR, n = 7; WKY, n = 7; 
PRET, n = 7) 
p values are results of grouped t-test comparing 






























































0.82 + 0.11 
0.95 + 0.13 
0.91 + 0.05 
0 .76 + 0.11 
0.81 + 0.12 
0.77 + 0.04 
0.73 + 0.11 
0.70 + 0.11 
0.73 + 0.05 
0.69 + 0.10 
0.67 + 0.11 




2.84 + 0.47 
2.16 + 0.52 
2.52 + 0.53 
2.44 + 0.38 





34.66 + 5.72 
21.90 + 4.86 
29.13 + 7.05 
30.61 + 4.17 





18.59 + 2.88 
15.09 + 3.70 
18.81 + 3.71 
17.53 + 2.43 
12.57 + 2.42 
1.91 + 0.40* 21.29 + 4.98** 14 .27 + 2.62 
2.05 + 0.49* 25.74 + 5.89* 13.83 + 2.27 
1.88 + 0.37 20.50 + 3.73 14.67 + 2.62 
2 .09 + 0.42** 23.83 + 5.03 16.03 + 2 .78 
1.92 + 0.50* 23.77 + 5 . 26* 13.40 + 2.27 
1.60 + 0.33** 18.84 + 3.98** 13.69 + 2.54 
1 . 84 + 0.54* 21 .89 + 6.69 14.73 + 3.53 
Data are mean + standnrd error 
(SHR, n = 7; WKY, n = 7; PRET , n = 7) 
>'<p < 0. 01 




159.29 + 8.04 
Time to Half 
Relaxation 
(msec) 





244.29 + 27.78 
194.29 + 2.65 110.00 + 9.92 272.14 + 18.71 
174.1 3 + 2 .57 93.34 + 2.57 225.56 + 7 .37 
158.57 + 4.03 96.43 + 6.42 225.00 + 14.49 
187.86 + 5.32 113.57 + 9.22 262.14 + 22.24 
173.16 + 5.39 89.93 + 6.02 220.34 + 13.53 
159. 29 + 4.42 92.86 + 8.43 221.43 + 19.33 
175.71 + 5.27 89.29 + 6.48 225.00 + 15 . 17 
168.81 + 6.68 84.27 + 4.65 212.87 + 19.74 
146.43 + 8.28 95.71 + 8.04 227.14 + 21 . 76 
157.14 + 5.95 93.57 + 6.23 220.00 + 8 . 71 




Percentage of Control Data f or the Effects of Acidosis on Papillary Musc·le Mechanics 
Maximal Rate Maximal Rate 
Resting Developed of Tension of Tension Time to Time to Half 
Time Rat. Tension Tension Development Dec~ine Peak Tension Relaxation 
(min) Type (g/mm2) (g/mm2) (g/mm2sec) (g/mm sec) (msec) (msec) 
5 WKY 93.6 + 3.1 87.9 + 6 . 5 93.1 + 9 . 8 96 . 6 + 8.1 100 .5 + 3.4 94.3 + 5 . 4 
SHR 82.8 + 5 . 7 91.2 + 10.7 87 . 9 + 7.7 90 . 2 + 8.4 96.9 + 2.1 104.6 + 5 . 6 
PRET 84 .1 + 1.7 76.7 + 4 . 5 74.4 + 5.0 76 . 8 + 4.9 99.6 + 2.1 96 . 0 + 4.0 
30 WKY 88.4 + 4.4 69.4 + 5.9 71.2 + 4.8 76.1 + 6 .4 101.2 + 4 . 7 88 . 8 + 4 . 9 
SHR 72 . 4 + 4.5 93.0 + 10.0 100 .3 + 10.3 108.5 + 14. 0 91.0 + 3.9 84 . 2 + 7 . 6 
PRET 79 . 3 + 2.4 84.6 + 4.9 85 .9 + 4.7 87.8 + 2 . 6 97.1 + 2.8 90.0 + 2 . 9 
60 WKY 85.6 + 6.0 63.2 + 6 . 7 65.9 + 5 . 2 73.6 + 7.6 94 . 2 + 7.7 93.9 + 4.2 
SHR 67 . 7 + 4.9 76 . 5 + 4.8 86.9 + 4 . 4 97 . 1 + 7 . 5 81.6 + 4.7 88 . 3 + 7.3 
PRET 73 . 5 + 2 . 9 66.8 + 6.9 68.9 + 7 . 1 74.7 + 5.2 93 . 7 + 2 . 6 85 . 1 + 5.4 
Data are mean + standard error 





96 . 6 + 7 . 9 
96.1 + 4 . 2 
97 . 5 + 4 . 2 
93 . 5 + 5.2 
84 .1 + 6 . 3 
92 . 0 + 5.9 
94.8 + 4.7 
83.5 + 7.4 




contr actility in each group of rats prior to any interven-
tion . Contractility of pretreated rats decreased 
significantl y from control after 5 minutes of acidosis by 
7 . 84 (p < 0 . 05) and that of WKY decreased significantly from 
control after 30 minutes by 8 . 92 (p < 0 . 0 1 ) . No significant 
change was observed between SHR and i t s control. 
A positive inotropic effect was found to result 
from the changi ng of extracellular calcium from 1 . 0mM Ca++ 
to 2 . 5mM Ca 
++ 
in the muscle bath during acidosis (Figures 8 
and 9) • During this intervention , no significant differ-
ence was observed in WKY , SHR or pretreated r ats studied. 
The nor malized data of each group of rats were compared to 
that o f its own control to d e t e rmine the e ffe cts of 
increase e xtra cellular Ca++ on muscle mechanics (Table 11) . 
Significant increases in de v e loped t e nsion and rate o f 
tension deve lopment were noted for the three groups o f 
rats at 5, 15, and 30 minute s of this intervention . 
Table 12 expresses the normalized data as p e rcent c ontrol . 
Re sponse to Hypoxia During 
Acidosis and Reoxygenation 
at Normal pH 
In this part of the protocol , muscle s in 2 . 5mM 
Ca++ were made acidic and then reoxygenated a t normal pH. 
Hypoxia at acidic pH cause d profound depression of muscle 
contraction . However, muscles reapproximate d pre hypo xic 
v a lues after reoxygenation. Table 13 presents the 


























0.69 + 0 . 10 
0.70 + 0 . 11 
0.67 + 0 . 05 
0 . 75 + 0.12 
0.69 + 0.13 
0.69 + 0.05 
0.77+0.10 
0.67 + 0.12 
0.66 + 0.05 
0.73 + 0.11 
0.66 + 0.13 
0 . 65 + 0.04 
Data are mea n + standa rd 
(SHR, n = 7; WKY, n = 7; 
*p < 0 . 01; **p < 0 . 05 
Deve loped 
Tensi~n 
(g/ mm ) 
1.92 + 0.52 
1.60 + 0.33 





23.77 + 5.26 
18.73 + 3.99 
21.89 + 6 . 69 
Maximal Rate 






13 . 40 + 2.27 146.43 + 8.28 
13.57 + 2.57 159 . 29 + 6.48 
14.7 3 + 3.53 161 . 04 + 4.95 
Time to Half 
Re laxati on 
(mse c} 
Time t o 
Ma ximal 
Relaxa tio n 
(ms e c} 
95.71 + 8 . 04 227 . 14 + 21.76 
93.57 + 6.23 224.29 + 11.40 
79.16 + 4 . 95 19 3.16 + 18.04 
2.71 + 0.56** 32.04 + 5 . 79* 16.86 + 2.52 157.14 + 4.85 107 . 14 + 8 . 07 "247.14 + 19 .90 
2 . 26 + 0.44* 24.91 + 4.45* 16 . 34 + 2 . 73 166.43 + 8 .13 
2.48 + 0.61* 29.00 + 7 . 39* 17.29 + 3 . 28 157.77 + 4.6 2 
2.61 + 0.63** 32.31 + 6.70* 17.70 + 3.16 135.00 +10.78 
2 . 03 + 0.38* 23.43 + 4.23* 15.01 + 2.29 164.29 + 8 . 40 
2.41 + 0.55* 30.10 + 7.13* 16 . 70 + 2.87 156.44 + 5.05 
2 . 68 + 0.65** 32.49 + 6.93* 17.90 + 3.24 152 . 14 + 1.84 
1. 8 3 + 0 . 32 22.33 + 4.02** 14.56 + 2.48 160 . 71 + 6.01 
2 .36 + 0.50* 28.90 + 6.63* 16 . 81 + 2.75 155. 14 + 5. 33 
error 
PRET, n = 7) 
97.14 + 7 . 21 251.43 + 33.30 
88.71 + 9.21 216.60 + 25 . 09 
85.71 + 10.42 217.14 + 26.79 
93 . 57 + 5 . 42 232.14 + 16.52 
86 . 46 + 7.09 214.93 + 25.2 2 
93 . 57 + 10.49 251 . 43 + 22 . 05 
9 2. 86 + 6. 52 21 3 .57 + 24.55 




Percentag e of Control Data of Papillar¥ Muscle Mechanics Due to Increase Extrace~lular 
Calcium From l.OmM Ca +to 2. 5mM ca++ During Acidosis 
Maximal Rate Max imal Rate 
Res ting Developed of Tensio n of Tension Time to Time to Half 
Time Rat . Tension Tension Development Decline Peak Tension Relaxatio n 
(min) Type (gj mm2) (g/ mm2) (gj mm2 s ec) (g/ mm2 sec) (msec) (msec ) 
5 WKY 108.9 + 5 . 0 151.0 + 13.1 139.9 + 10.5 127.6 + 8.6 108 . 9 + 5 . 4 112 . 7 + 4 . 5 
SHR 98 . 4 + 5.6 142 . 2 + 10.3 137.5 + 9 . 0 122.9 + 7 . 9 106 . 2 + 5.0 104.5 + 6 .1 
PRET 102.8 + 2.7 143.2 + 10 . 7 146 . 4 + 14.7 127.3 + 11.8 97 . 3 + 2.9 111.9 + 8.6 
15 WKY 115.2 + 8.8 138 . 1 + 15.6 137.5 + 15.4 129 . 0 + 13.0 94.9 + 11.5 90 . 0 + 8.2 
SHR 99.6 + 2.7 129.0 + 4.8 127.7 + 4 . 0 113.3 + 5 . 7 104.9 + 5 . 5 100 . 9 + 4.5 
PRET 100 . 0 + 0.0 142 . 7 + 13 . 2 152.4 + 18 . 0 125 . 9 + 14.2 97.3 + 2.4 109.1 + 5 . 9 
30 WKY 109.6 + 9.5 143 . 6 + 19 . 1 139.8 + 18 . 2 130.8 + 12.0 1 05 . 9 + 6 . 4 97.1 + 6 . 4 
SHR 94.3 + 6.0 113 . 1 + 6.8 119.4 + 7.5 107.0 + 4 . 0 103.3 + 6 . 2 99 . 5 + 4.6 
PRET 96.6 + 2 . 2 145.4 + 14.7 151.6 + 20.1 128.6 + 14.4 96.6 + 3.1 110.4 + 5 . 1 
Data are me an + standa rd error 





110.2 + 5.6 
110.5 + 51.6 
111.8+ 5 . 7 
98.5 + 9.9 
106.0 + 7 . 0 
110.2 + . 5 . 2 
112.0 + 5 . 5 
98.0 + 11.4 




























0.73 + 0 . 11 
0.66 + 0.13 
0 . 65 + 0.04 
0 . 77 + 0.11 
0.74 + 0.15 
0. 72 + 0.06 
0.77 + 0.09 
0.78 + 0 . 18 
0.87 + 0 . 05 
0.81 + 0.11 
0 . 75 + 0.17 




2.68 + 0.65 
1.83 + 0.32 
2.36 + 0.50 





32.49 + 6.93 
22.33 + 4.02 





17 . 90 + 3.24 
14.56 + 2.48 
16 . 81 + 2.75 
26 . 40 + 5 . 77** 15 . 04 + 2 . 68 
1 . 16 + 0.17** 13 . 73 + 2. 1 7** 9 . 26 + 0.99 
1 . 43 + 0 . 25** 18 . 13 + 3.68** 10 . 94 + 1 . 50 
0.91 + 0. 1 8** 12.61 + 2.72** 7.90 + 1.57 
0.63 + 0.06* 7.30 + 0.90* 5 . 79 + 0.67 
0.68 + 0.11* 8. 39 + 1. 59* 6.10 + 0.62 
0.87 + 0.18** 10 . 84 + 2 . 07* 8.17 + 1.61 
0.60 + 0.10* 6.81 + 0.93* 5 . 73 + 0 . 71 
0 . 65 + 0.09* 8.19 + 1.42* 6.31 + 0.72 
Data are me an + sta ndard error 
(SHR, n = 7; WKY, n = 7; PRET , n = 7) 




152 . 14 + 1.84 
1 60.71 + 6.01 
155.14 + 5 . 33 
145.71 + 4 . 42 
154.29 + 6.84 
146 . 56 + 7.23 
142.14 + 4.06 
147 . 14 + 5.54 
132 . 19 + 5 . 13 
139.29 + 5 . 04 
152 . 14 + 6.88 
138.66 + 4 . 29 







93 . 57 + 1 0.49 251 . 43 + 22 . 05 
92.86 + 6 . 52 213.57 + 24.55 
87 . 13 + 6 . 13 213.53 + 26.28 
88.57 + 10.88 226 . 43 + 19 . 33 
98.57 + 4.45 242 . 86 + 1 0.72 
84.31 + 8.99 210.70 + 23.59 
83.57 + 6.95 243 . 57 + 21 . 94 
92 . 14 + 4 . 20 202.86 + 16.87 
80 . 47 + 9.76 224.07 + 15.37 
80 . 71 + 5.16 206 . 43 + 22 . 3 2 
85 . 00 + 7.23 207 . 14 + 14 . 36 




Percentage of Control Data for the Effects of H¥poxia on 
Papillary Muscles Exposed to 2.5mM Ca+ 
Maximal Rate Maximal Rate 
Resting Developed of Tension of Tension Time to 
Time Rat . Tension Tension Development Decline Peak Tension 
(min) Type (gjrnrn2) ( gjrnrn2) (gjrnrn2sec) (g/rnrn2sec) (msec) 
5 WKY 106 .7 + 8.8 85.0 + 7.1 84.0 + 6.9 85.4 + 5.7 95.7 + 2.5 
SHR 113.4 + 5.2 64.2 + 5.0 62.7 + 4.9 67.6 + 5.2 95 .5 + 3.5 
PRET 112 . 3 + 5.9 62 . 7 + 5 . 7 62.8 + 7.7 67.1 + 5.7 94.5 + 3.3 
30 WKY 98.5 + 6.7 42.9 + 9.4 41.1 + 5.6 43.9 + 4.6 93.4 + 2.3 
SHR 114.1 + 7.2 39.1 + 5.8 35.1 + 3.8 43.3 + 6.2 91.6 + 1.4 
PRET 121.1 + 6.7 31.4 + 4.1 31.6 + 4.0 39.9 + 4.7 85.4 + 3.2 
60 WKY 110.2 + 12.9 38 .5 + 6.6 36.2 + 4.3 46.2 + 3.4 91.5:!:. 2.7 
SHR 113.6 + 8.6 34 . 2 + 6.6 33.6 + 5.1 42.0 + 5 .5 94.8 + 3.3 
PRET 137.1 + 12 . 0 31.6 + 4.7 32.5 + 4.4 41.7 + 6.0 89.6 + 2.5 
Data are me an + standard error 
(SIIR, n = 7; WKY, n = 7; PRET, n = 7) 
Time to Half 
Relaxation 
(msec) 
98.2 + 10.5 
109.9 + 10.6 
96.4 + 7.9 
92.1 + 6.1 
102.6 + 9.3 
92.3 + 8.5 
93.7 + 12.3 
94.0 + 9.4 





94 . 7 + 12.5 
126.4 + 19.8 
103.3 + 12.0 
101.0 + 13.5 
108.4 + 23.8 
110.2 + 8.9 
87.6 + 14.8 
109 . 1 + 19.8 
97.2 + 8 .9 
~ 
CXl 
expresses this data as percent of control. Table 13 shows 
that RT of PRET increased significantly at 60 minutes of 
hypoxia. It shows that the +dT/dt, an indication of con-
tractility, was significantly lower than the controls in 
69 
all three groups of rats (WKY, SHR, and pretreated rats) 
after 5, 30, and 60 minutes of hypoxia. Figures 8 and 9 do 
not show any significant difference between WKY and SHR,_ 
WKY, and pretreated rats, and SHR and pretreated rats after 
60 minutes of hypoxia, but after 5 minutes of hypoxia 
(Table 14), a significant difference (p < 0.05) in DT and 
+dT/dt between SHR and WKY was observed. Both DT and 
+dT/dt were greater for WKY than for SHR -(Table 14). During 
hypoxia, the TPT, RT%, TPR and, therefore, the contraction 
cycle, were shortened. There was a significant difference 
(p < 0.01) _ before and after hypoxia. Readings before hypoxia 
were higher than those after hypoxia. 
Tables 15 and 16 show reoxygenation after hypoxia. 
Table 15 shows that the RT of PRET which increased signifi-
cantly at 60' of hypoxia decreased significantly at 30' of 
reoxygenation. During reoxygenation the parameters of 
muscle mechanics all increased and reapproximated their 
prehypoxic state. All the parameters except for the rest-
ing tension were significantly higher than their controls. 
As seen in Figures 8 and 9, the WKYs, SHRs, and pretreated 
rats responded almost equally to reoxygenation. No signi-































0.81 + 0.11 
0.75 + 0.17 
0.85 + 0.05 
0. 77 + 0 . 13 
0.72 + 0.20 
0.81 + 0 . 06 
0.76 + 0.13 
0.73 + 0.23 
0.77+0.06 
0.71 + 0 . 13 
0.78 + 0.25 
0. 77 + 0.06 
0.70 + 0.14 
0.77 + 0.28 




0.87 + 0.18 
0.60 + 0.10 





10.84 + 2.07 
6.81 + 0 . 93 
8.19 + 1.42 
2.21 + 0.83* 23.57 + 7.09* - -
2.14 + 0.53* 24.33 + 5.84 * - -
1 . 79 + 0.24* 20.83 + 3.14* 
2 .67 + 0.70* 
2 . 16 + 0.48* 
2. 26 + 0.36 * 
31.74 + 7 .32'~ 
25.19 + 5.05* 





8.17 + 1.61 
5.73 + 0.71 




139.29 + 5.04 
152.14 + 6.88 
138.66 + 4.29 
15 . 26 + 6 . 47 * 150.71 + 5.16 - -
13 . 84 + 2.83* 161.43 + 6.60 - -
11.87 + 0.96* 155.96 + 6.21 
18 . 46 + 5.81* 150.00 + 5.11 - -
15.26 + 2.71* 160.71 + 6.57 - -
15.07 + 1.44* 149.87 + 4.33 
2.82 ± o.65* 34.81 ± 7 . 54 * 20.40 ± 5.5o* 146.43 ± 5.94 
2 .11 + 0.47* 24.67 + 5.17 * 15.20 + 2.79* 157.14 + 6.34 - - - -
2.36 + 0.37 * 29 .47 + 5.38 * 17.03 + 1.79 * 147.87 + 4.45 
2 . 93 + 0.61'"" 37.46 + 7.49 ' '< 22.54 + 5.34* 144 .23 + 6.11 - - - -
2. 10 + 0.47 "'' 25.70 + 5.28'" 17.17 + 3.33* 147.86 + 4. 20 - - - -
2 .18 + o.44 * 3 l .oo + 5.88 * 18.74 + 2.32* 138.84 + 4.12 
Da t a are mean ~ standard error 
(SHR, n = 7; WKY , n = 7 ; PRET , n = 7) 
*p < 0 . 0 1; **p < 0 . 05 
Time to Half 
Relaxation 
(msec) 












95.00 + 11.88 
102.86 + 10.44 





206.43 + 22.32 
207.14 + 14. 36 
197.50 + 16.90 
245.71 + 18.31 
248 .57 + 25.98 
247.26 + 13.55 
250.71 + 2 j.23 
262.14 + 31.81 
241.63 + 21.71 
87.14 + 8 .9 1 248.57 + 25.70 - -
98.57 + 9.03 229.29 + 22.47 - -







220.00 + 11.98 
220.00 + 1 7 . 70 










Percentage of Control Data for the Effects of Reoxygenation on 


















93.0 ~ 7.0 
94 . 0 :!: 5 . 6 
93 . 0 ~ 2 . 5 
91.3 :!: 10.0 
91.6 ± 7 . 8 
89.2 ~ 3.6 
85.6 ~ 9 . 9 
95 . 5 ± 8.3 
89.2 ± 3 . 6 
83 .7:!: 11.5 
92 . 6 ± 10 . 8 








230.2 ~ 49.7 207.3 ± 44.1 




(g / mm2sec) 
164.2 :!: 42.2 
223.6 :!: 30 .9 
301. 6 ± 44.4 277 .7 ± 33.0 201 .4 ± 26.4 
299.4 ~ 49.7 
348 . 6 ± 49.7 
361.1:!: 41.9 
320.9 :!: 46.4 
348 .9 ~ 62.1 
366.3:!: 31 .9 
290.5 ~ 5 1.1 
353.9 :!: 54.0 
350.5 ± 30 .9 
316.6 ± 48.4 
354.4 :!: 64.3 
357 .2 :!: 22.5 
211. 4:!: 37.7 
253 . 4 ± 24.4 
251 . 8 :!: 32.2 
238 . 4:!: 33 . 1 
253 . 9 ± 27 . 8 
28 1.1 :!: 32 . 9 
344.4 ± 40 . 2 349.0:!: 41.6 275 .7:!: 27.0 
351. 7:!: 69 . 9 371 . 8:!: 70 .4 286.7 ± 37.6 
361.0:!: 29 . 0 378.9 ± 28 . 5 304. 1 :!: 32.1 
Data are mean ± standa rd err or 




108 . 6 ± 3.5 
107.0:!:: 4.7 
112.5 :!: 3.1 
108 .0 ± 3.0 
106.0 :!: 6.2 
108 . 3:!:: 2.7 
105.2 :!: 2.6 
103 . 5 ± 5.6 
106.8 :!: 2.4 
102.9 :!: 3 . 5 
97 . 4:!: 6. 1 
98 . 8:!: 1 . 9 
Time to Half 
Relaxation 
(msec) 
125 .1:!: 12 .7 
136.7 ± 22.6 
112.3 ± 7.6 
122.2 :!: 19.6 
132.3 :!:: 25 . 0 
104. 1 ± 10 . 4 
111.4 ± 14 .6 
122 . 0 :!: 16.8 
93.2 ± 9 .1 
105.1 ± 11.2 
12 1. 2 :!: 17.0 





127.1 :!: 15 . 7 
120 . 4 :!: 11 . 3 
130.0 ± 12 . 7 
128 . 1 :!: 15. 1 
127.9 ± 16.8 
127.8 :!: 17.3 
129.6 ± 18 . 4 
113.0:!: 1 3 . 1 
11 5 .4:!: 13.0 
11 3.6 ± 12 . 1 
108. 5 ± 11 . 1 





Clonidine effected a significant decrease (p < 0. 01 >. 
in the blood pressures of spontaneously hypertensive rats 
after chronic treatment, as was shown by Dadkar, Aroskar, 
and Dohadwalla (1979), who administered clonidine orally 
for 5 days to SHRs. The only problem encountered with this 
treatment was that most of the rats died during blood 
pressure monitoring. All showed the same pattern of 
"frothing,. from nose and mouth before dying. At autopsy, 
hemorrhage was found in their lungs. No data has been able 
to explain this effect. Possibly the sensitivity of the 
rat to heat may be affected by the continuous administra-
tion of clonidine. This may indicate thermoregulatory 
dysfunction in SHRs which may be of central origin. It is 
known that SHRs have a higher basal body temperature and 
are more sensitive to heat (O'Donnell and Volicer, 1981; 
Wilson, Wilson, and DeCara, 1977; Wright, Lams, and Knecht, 
1977). O'Donnell and Volicer (1981) showed that treatment 
with clonidine and other antihypertensives decreased the 
blood pressures of SHRs but did not normalize body tempera-
tures or heat sensitivity. 
Alpha-methyldopa produced a significant hypotensive 
effect on the blood pressures of the SHRs in this study. 
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Other investigators (Day, Roach, and Whiting, 1972; 
Filczewski and Boqucka, 1979; Zavisca et al., 1979) have 
also shown hypotensive effects of alpha-methyldopa in the 
SHR. 
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Verapamil was found to be very effective in causing 
a significant decrease in blood pressure. Data pertinent 
to the hypotensive action of verapamil following long-term 
oral therapy are few. Nevertheless, in several studies 
with the drug in angina, blood pressure was found to be 
lowered by verapamil when administered to mildly hyperten-
sive patients with ischemic he art disease (Hoffman, 1964; 
Lewis, 1978; Lewis et al., 1979; Livesley et al., 1973; 
Tschirdewahn and Klepzig; 196 3). Oates, Stoker, and 
Stokes (1979), using unanesthesized rats, also showed that 
verapamil can be an .effective hypotensive agent. 
Propranolol treatment produced variable effects on 
the blood pressures of spontaneously hypertensive rats. 
This variability of response was consistent with some 
previous reports (Forman and Mulrow, 1974; Levy, 1976; 
Numao and Iriuchijima, 1974). Others (Garvey and Ram, 
1975; Sweet et al., 1976; Vavra, Tom, and Greslin, 1973) 
showed that propranolol had a hypotensive action on the 
blood pressure of spontaneously hypertensive rats. Hypo-
tensive action was also observed by Smits, Van Essen, and 
Struyker-Boudier (1980) when propranolol was delivered for 
5 days to conscious, unrestrained spontaneously hypertensive 
rats using osmotic minipurnps. Close comparison of the 
results of these studies is hampered by differences in 
experimental conditions, such as the use of anaesthetics, 
methods of pressure measurement, dosages used and the 
schedule of drug administration. 
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Cardiac hypertrophy, which has always been associ-
ated with hypertension, is also present in the spontaneous 
hypertensive rat. This rat, therefore, offers a unique 
model for studying the reversal of cardiac hypertrophy by 
medical therapy. Systematic investigation led to the 
suggestion that factors other than arterial pressure are 
involved in the development of cardiac hypertrophy in 
hypertension (Sen et al., 1974). Results of the present 
study showed that the antihypertensive drugs used to treat 
the SHRs chronically did not cause a significant reduction 
of heart weight to body weight ratio. This finding 
suggests that decreasing blood pressure by pharmocologically 
alone, at least for a 6-week period, may not reverse hyper-
trophy. On the other hand, the mechanism of action of the 
antihypertensives--such as the effect on hemodynamic, 
humoral, and/or neurogenic factors--might also be very 
important in reversing cardiac hypertrophy. A biochemical 
effect of the drugs on cardiac muscle is another possibility. 
Sen et al. (1977) carne to the tentative conclusion that 
sympathetic stimulation and hemodynamic factors might play 
more important roles. 
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In spontaneously hypertensive rats, the abilities 
of the cardiac and vascular smooth muscle to retain calcium 
(by depressed calcium binding and accelerated ATP split-
ting) and to take ATP-dependent calcium into the sarco-
plasmic reticulum are less than those of normotensive rats 
(Aoki et al., 1974a, 1974b; Aoki, Yamashita, and Hotta, 
1976; Moore et al., 1975). The way in which SHRs and WKYs 
handle calcium during a cardiac cycle can be affected by 
different pharmacologic or physiologic interventions. 
Isoproterenol, a beta-receptor agonist, has a 
positive inotropic effect on the myocardium of most species. 
Isoproterenol relaxes almost all varieties of smooth muscle. 
Isoproterenol has a relaxing effect on the isolated thoracic 
aorta. Spector e t al. (1969) found this relaxing effect 
greater for SHRs than for WKYs. Others found the relaxa-
tion of the SHR thoracic aorta to be l ess than that of the 
WKY (Cohen and Berkowitz, 1976; Triner et al., 1975); still 
others found that relaxation was equal in both SHR and WKY 
(Levy, 1974; Shibata, Juraha shi, and Kuchii, 1973). Limas 
and Limas (1978) observed a decrease d number of beta-
receptors in the hearts of SHRs, and therefore a decreased 
sensitivity to catecholamines. Since isoproterenol causes 
the stimulation of beta-receptors, its effect is neces-
sarily lower in SHR than in WKY, due to the decreased 
numbe r of beta-receptors. In the present study, a few 
minutes after isoproterenol was added to the papillary 
muscle in the absence of propranolol, a significant change 
in performance from control was observed in both the SHR 
and WKY. The tension developed by the papillary muscles 
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of both SHR and WKY was only moderately depressed. The 
depression was equal in both SHR and WKY. Overall con-
tractility (+dT/dt) was not depressed in WKY but was 
depressed at 15 minutes in the SHR. Fifteen minutes after 
the addition of isoproterenol, the time to peak r e laxation 
of papillary muscles from WKYs was significantly d e pressed 
when compared to their control. The time to half relaxation 
of the papillary muscles showed that 1 minute after the 
addition of isoproterenol to the bath, the WKY responded 
significantly differently from the SHR. The time to half 
relaxation was longer for WKY than for SHR, but after 
several minutes, the time to half relaxation became almost 
equal for the SHR and WKY. 
Propranolol, that was added to muscle bath, causes 
beta adrenergic receptor blockade, which produces meta-
bolic rearrangements in myocardial cells and also decreases 
penetration of ionized calcium into the cytoplasm 
(Kukovetz and Poch, 1976). Propranolol has been shown to 
cause negative chronotropic and inotropic effects. The 
results of the present study indicate that the developed 
tension of papillary muscles from WKY and SHR were 
significantly depressed at 1 and at 5 minutes following 
propranolol addition, whereas the developed tension of 
muscles from SHR only was significantly depressed 10 
minutes after the addition of propranolol. This result 
indicates a possible difference in sensitivity to receptor 
sites. Propranolol also caused significant decrease in 
+dT/dt of the WKYs and SHRs after 5 minutes addition, 
indicating significant relaxation. Ten minutes following 
this intervention, only the dT/ dt and -dT/ dt of the WKY 
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was significantly decreased. Also the TPR of SHRs were 
significantly decreased after 10 minutes of addition. A 
significant difference (WKY lower than SHR) in the developed 
tension of the WKYs and SHRs was noted 5 minutes following 
intervention with propranolol. This result suggests a 
difference in the sensitivity to propranolol of the beta-
receptors of SHRs and WKYs. 
When isoproterenol was added to the bath after 
propranolol, only the muscles from the WKYs showed a 
significant recovery from the effect of the propranolol. 
This also suggests a possible difference in the way WKYs 
and SHRs respond to propranolol. 
Acidosis resulted in a significant decline in 
muscle contractility. Nakamuru and Schwartz (1970) and 
Williamson et al. (1975) suggested that, at low pH, excess 
hydrogen ions compete with calcium ions for binding sites 
to the myocardial protein troponin and increase the binding 
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of calcium ions to the sarcoplasmic reticulum. The present 
study showed that after 5 minutes of acidosis, the developed 
tension and the rate of tension development of only the 
pretreated rats were significantly depressed compared to 
their control. After 30 minutes of acidosis, the developed 
tension of the SHRs and pretreated rats were significantly 
depressed when compared to their controls, while the +dT/dt 
of only the pretreated rats was significantly depressed. 
At 60 minutes of acidosis, the maximal rates of tension 
development of all the three groups of rat were depressed 
significantly. The present study also found that the rate 
of tension development of the WKY was significantly less 
than that of the SHR at 30 and at 60 minutes of acidosis. 
The rate of tension decline was also significantly lower for 
both the WKY and the pretreated rat and higher for the SHR. 
These results suggest a difference in the way the WKYs, 
SHRs and pretreated rats respond to acidosis: SHRs 
appeared to be less sensitive to the depressing effects of 
acidosis. Figures for developed tension and rate of ten-
sion development indicate a difference in amount/rate of 
intracellular calcium release, suggesting that the differ-
ences among these groups in response to acidosis has some-
thing to do with the handling of calcium. 
An increase in extracellular calcium resulted in 
improvement in every area of muscle performance studied. 
Developed tension and maximal rate of tension development 
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were significantly increased for the WKYs, SHRs, and pre-
treated rats. The three groups of rats responded almost 
equally to this intervention. Increased extracellular 
calcium did not override the effects of acidosis as well in 
SHRs as in the other groups, indicating a difference, at 
least during acidosis, in their responsiveness to increased 
calcium. 
Hypoxia caused a significant decline in performance 
in all areas studied. Hypoxia decreases tissue oxygen 
availability while reoxygenation elicits rapid increases 
in tissue consumption (Whaler, 1967). Because oxygen is 
needed for oxidative phosphorylation, hypoxia results in 
decreased amounts of energy available for the contraction-
coupling process. Tyberg et al. (1969, 1980) studied the 
effects of hypoxia on papillary muscle mechanics and hypo-
thesized that a reduced amount of calcium might enter the 
myoplasm during hypoxia, activating only the peripheral 
portions of the myofibrils. The present study found that at 
5, 30, and 60 minutes of hypoxia, the DT and +dT/dt were 
significantly depressed for the WKYs, SHRs, and pretreated 
rats. SHRs, pretreated rats, and WKYs responded differently 
in the early stages of hypoxia, but this was a transient 
effect. Perhaps in the early stages of hypoxia SHRs 
experienced more rapid depletion of available o2 . Since 
calcium stores were more rapidly depleted in SHR, there 
should have been a decrease in developed tension. Depletion 
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was further compounded by the acidic medium. Lowered 
calcium resulted in less ATP. Nayler et al. (1979) showed 
that mild acidosis has a protective effect on hypoxic heart 
muscle, resulting in a relatively small rise in resting 
tension. The present study found a small rise in resting 
tension of the WKY, and, in the SHR, a greater rise at 5 
minutes of hypoxia and then a smaller rise with time. This 
difference, observed at the early stage of hypoxia, indicates 
that acidosis did not have much protective effect in SHR. 
When muscles were reoxygenated after hypoxia, 
performance parameters reapproached prehypoxic values to 
varying degrees. SHRs, WKYs and pretreated rats responded 
almost equally during reoxygenation. Nayler et al. (1979) 
observed a greater recovery of tension development during 
reoxygenation when hypoxia occurred at acidic pH than when 
it occurred at normal pH. Lakatta, Nayler, and Poole-Wilson 
(1979), measuring mechanical function and calcium accumula-
tion in isolated normotensive muscle, found that when 
hypoxia was induced at low pH (6.8), subsequent reoxygena-
tion at normal pH was not associated with calcium overload 
or the development of contracture. The phenomenon of 
calcium overload during hypoxia and reoxygenation has not 
been examined in hypertensive cardiac muscle, but the results 
of the present study show that SHR behaved differently from 
WKY during hypoxia and subsequent reoxygenation, suggesting 
that acidosis has less protective effect on SHR. 
Chapter 5 
SUMMARY OF RESULTS AND CONCLUSIONS 
1. Clonidine, alpha-methyldopa, and verapamil 
reduce blood pressure of SHRs. 
2. Isoproterenol did not have a significant 
inotropic effect on isolated cardiac muscle obtained from 
SHRs or WKYs. 
3. Propranolol significantly depressed +dT/dt only 
in the WKYs, showing that SHRs behave differently from WKYs. 
4. Acidosis significantly depressed muscle 
performance in SHR, WKY, and pretreated papillary muscles. 
However, +dT/dt and -dT/dt were decreased significantly 
less in the SHR than in the other groups, indicating that 
SHRs are less sensitive to acidosis. 
5. Increasing extracellular calcium from 1.0 to 
2.5 mM significantly increased the inotropic state of all 
three groups of muscles. 
6. Hypoxia during acidosis significantly decreased 
muscle performance in all three groups. At 5 minutes 
hypoxia, however, WKY was less depressed than SHR; this 
shows that WKYs are less sensitive to hypoxia. 
7. Reoxygenation at normal pH resulted in muscle 
improvement of a similar magnitude in all three groups, and 
no increases in resting tension were observed, indicating 
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that acidosis has a protective effect on muscles made 
hypoxic, thereby preventing contracture and subsequent 
death of the muscle during reoxygenation at normal pH. 
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